Amplification of HER2 facilitates hyperactivated signaling of RAS/RAF/MAPK kinases which in turn sharply upregulates cyclin D1, leading to dysregulation of the G1/S checkpoint that plays a crucial role in breast cancer, being overexpressed in 40% of most cases [52]. This evidence concerns the gene CCND1 and breast carcinoma.